What side effects are associated with this type of intervention?

Common treatments for high blood pressure include ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, beta blockers, and magnesium supplementation. ACE inhibitors and ARBs can cause side effects such as cough, elevated blood potassium levels, and kidney dysfunction. Calcium channel blockers may lead to swelling, dizziness, and constipation. Thiazide diuretics are associated with electrolyte imbalances, such as low potassium and sodium levels, and can increase the risk of gout. Beta blockers can cause fatigue, cold extremities, and bradycardia. Magnesium supplementation, while generally well-tolerated, can cause gastrointestinal discomfort and diarrhea.

What prior FDA approvals exist?

The FDA has approved several classes of drugs for the treatment of high blood pressure that improve vascular tone and function. These include calcium channel blockers (CCBs) like amlodipine, which relax blood vessels by inhibiting calcium entry into cells. Angiotensin-converting enzyme (ACE) inhibitors such as lisinopril and angiotensin II receptor blockers (ARBs) like losartan also help by relaxing blood vessels and reducing blood pressure. Additionally, diuretics like indapamide are used to lower blood pressure by reducing fluid volume in the body. These treatments are similar in their vascular effects to the magnesium glycinate being studied for its potential to lower blood pressure.

What other types of research exist?

Promising alternatives to Magnesium Glycinate for high blood pressure treatment include: 1) Sacubitril/Valsartan (an angiotensin receptor-neprilysin inhibitor) which has shown efficacy in reducing blood pressure and improving cardiovascular outcomes. 2) Folic Acid combined with Enalapril, which has been effective in reducing the risk of first stroke in hypertensive patients. 3) Branched-chain amino acids (BCAAs) which have shown potential in improving vascular function. These alternatives offer novel mechanisms and have demonstrated benefits in clinical settings.

← Back to Search

Mineral Supplement

Magnesium Supplementation for High Blood Pressure

N/A

Recruiting

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Total magnesium intake from supplements of no more than 100 mg/day

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 12 week

Awards & highlights

Study Summary

This trial examines if taking 480mg of magnesium daily for 12 weeks can lower blood pressure.

Who is the study for?

This trial is for adults with a self-reported systolic blood pressure between 125-159 mmHg and measured seated systolic blood pressure of 130-159 mmHg. Participants should have a BMI under 40, take no more than 100 mg/day of magnesium from supplements, and be willing to keep their diet the same during the study. People with severe high blood pressure, certain chronic diseases, or those who are pregnant or planning to move away can't join.Check my eligibility

What is being tested?

The trial is testing if taking a daily dose of magnesium glycinate (480 mg) for three months can lower high systolic blood pressure compared to a placebo. The participants will either receive the supplement or an inactive pill without knowing which one they're getting.See study design

What are the potential side effects?

Magnesium supplements may cause digestive issues like diarrhea or stomach cramps in some people. High doses might lead to more serious problems such as irregular heartbeat but this is rare especially at controlled doses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I take 100 mg or less of magnesium supplements daily.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 12 week

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 12 week

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in seated diastolic blood pressure from baseline to 12 weeks

Change in seated systolic blood pressure from baseline to 12 weeks

Secondary outcome measures

Change in RBC magnesium levels from baseline to 12 weeks

Change in serum magnesium levels from baseline to 12 weeks

Whether the effect of magnesium on seated blood pressure is modified by baseline serum and/or RBC magnesium

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: magnesiumActive Control1 Intervention

magnesium glycinate supplement, 480 mg/day

Group II: placeboPlacebo Group1 Intervention

placebo supplement

0 / 1Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for high blood pressure include ACE inhibitors and ARBs, which relax blood vessels by inhibiting the renin-angiotensin system; calcium channel blockers, which prevent calcium from entering heart and blood vessel cells, leading to relaxed vessels; diuretics, which reduce blood volume by increasing urine output; and beta-blockers, which decrease heart rate and output. Magnesium supplementation, like magnesium glycinate, improves vascular tone and function, potentially lowering blood pressure by relaxing blood vessels and enhancing endothelial function. These mechanisms are crucial for managing high blood pressure as they help reduce the risk of cardiovascular events and organ damage.

Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.Management of life-threatening autonomic hyper-reflexia using magnesium sulphate in a patient with a high spinal cord injury in the intensive care unit.